Literature DB >> 24126079

Research gaps in psoriasis: opportunities for future studies.

Caitriona Ryan1, Neil J Korman2, Joel M Gelfand3, Henry W Lim4, Craig A Elmets5, Steven R Feldman6, Alice B Gottlieb7, John Y M Koo8, Mark Lebwohl9, Craig L Leonardi10, Abby S Van Voorhees11, Reva Bhushan12, Alan Menter1.   

Abstract

Over the past 2 decades, considerable progress has been made to further elucidate the complex pathogenesis of psoriasis, facilitating the development of a new armamentarium of more effective, targeted therapies. Despite these important advances, substantial deficits remain in our understanding of psoriasis and its treatment, necessitating further research in many areas. In the sixth section of the American Academy of Dermatology Psoriasis Guidelines of Care, gaps in research and care were identified. We discuss the most important gaps in research that currently exist and make suggestions for studies that should be performed to address these deficits. These encompass both basic science and clinical research studies, including large, prospective epidemiologic studies to determine the true prevalence and natural history of psoriasis; further molecular studies in patients with psoriatic and psoriatic arthritis to understand the function of psoriasis susceptibility genes and to identify novel therapeutic targets; studies to examine the role of environmental factors in the development of psoriasis; further investigation of the relationship between psoriasis and cardiometabolic disease; studies that examine the role of adjunctive therapies such as psychological interventions in appropriate patient groups; and finally, studies to identify biomarkers of disease severity and treatment response to optimize patient therapy.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  ACR; American College of Rheumatology; C-reactive protein; CRP; FDA; Food and Drug Administration; IFN; IL; MACE; MI; NB; NIH; National Institutes of Health; PsA; RA; RCT; TNF; UV; VEGF; adjunctive therapies; biologics; cardiovascular disease; comorbidities in psoriasis; comparative studies; disease severity; environmental factors in the development of psoriasis; future research studies; interferon; interleukin; major adverse cardiovascular events; methotrexate; molecular studies in psoriatic and psoriatic arthritis; myocardial infarction; narrowband; pathomechanisms and genetics of psoriasis; phototherapy; psoriasis; psoriasis guidelines; psoriasis treatment; psoriatic arthritis; psychological; randomized controlled clinical trial; research gaps; rheumatoid arthritis; therapeutic targets; topical therapies; tumor necrosis factor; ultraviolet; vascular endothelial growth factor

Mesh:

Substances:

Year:  2013        PMID: 24126079     DOI: 10.1016/j.jaad.2013.08.042

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  31 in total

1.  Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances.

Authors:  Andrew F Alexis; Paul Blackcloud
Journal:  J Clin Aesthet Dermatol       Date:  2014-11

2.  Increased prevalence of early repolarization in electrocardiograms of psoriatic patients.

Authors:  Mario Mastrolonardo; Girolamo D'Arienzo; Massimo Grimaldi; Marica Caivano; Domenico Bonamonte; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Heart Vessels       Date:  2014-12-31       Impact factor: 2.037

Review 3.  Galectin-3 in autoimmunity and autoimmune diseases.

Authors:  Felipe L de Oliveira; Mariele Gatto; Nicola Bassi; Roberto Luisetto; Anna Ghirardello; Leonardo Punzi; Andrea Doria
Journal:  Exp Biol Med (Maywood)       Date:  2015-07-03

4.  Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.

Authors:  Jalpa A Doshi; Junko Takeshita; Lionel Pinto; Penxiang Li; Xinyan Yu; Preethi Rao; Hema N Viswanathan; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2016-03-04       Impact factor: 11.527

5.  Psoriasis and psoriatic arthritis in African-American patients--the need to measure disease burden.

Authors:  Gail S Kerr; Seema Qaiyumi; John Richards; Hashem Vahabzadeh-Monshie; Chesahna Kindred; Sean Whelton; Florina Constantinescu
Journal:  Clin Rheumatol       Date:  2014-08-28       Impact factor: 2.980

6.  RAC1 activation drives pathologic interactions between the epidermis and immune cells.

Authors:  Mårten C G Winge; Bungo Ohyama; Clara N Dey; Lisa M Boxer; Wei Li; Nazanin Ehsani-Chimeh; Allison K Truong; Diane Wu; April W Armstrong; Teruhiko Makino; Matthew Davidson; Daniela Starcevic; Andreas Kislat; Ngon T Nguyen; Takashi Hashimoto; Bernard Homey; Paul A Khavari; Maria Bradley; Elizabeth A Waterman; M Peter Marinkovich
Journal:  J Clin Invest       Date:  2016-06-13       Impact factor: 14.808

7.  Antibiotic Exposure, Infection, and the Development of Pediatric Psoriasis: A Nested Case-Control Study.

Authors:  Daniel B Horton; Frank I Scott; Kevin Haynes; Mary E Putt; Carlos D Rose; James D Lewis; Brian L Strom
Journal:  JAMA Dermatol       Date:  2016-02       Impact factor: 10.282

Review 8.  Emerging biomarkers in psoriatic arthritis.

Authors:  So Yeon Paek; Ling Han; Matthew Weiland; Chuan-Jian Lu; Kathleen McKinnon; Li Zhou; Henry W Lim; James T Elder; Qing-Sheng Mi
Journal:  IUBMB Life       Date:  2015-11-24       Impact factor: 3.885

9.  FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.

Authors:  E Mendrinou; A Patsatsi; E Zafiriou; D Papadopoulou; L Aggelou; C Sarri; Z Mamuris; A Kyriakou; D Sotiriadis; A Roussaki-Schulze; T Sarafidou; Y Vasilopoulos
Journal:  Pharmacogenomics J       Date:  2016-04-05       Impact factor: 3.550

10.  Lifestyle changes for treating psoriasis.

Authors:  Shu-Hua Ko; Ching-Chi Chi; Mei-Ling Yeh; Shu-Hui Wang; Yu-Shiun Tsai; Mei-Ya Hsu
Journal:  Cochrane Database Syst Rev       Date:  2019-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.